Carlos Arellano Serrano

Dr. Carlos Arellano Serrano

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JCJorge Calderón-Parra
Jorge Calderón-Parra
JSJuan Esteban De Villarreal Soto
Juan Esteban De Villarreal Soto
JDJuan Francisco Oteo Domínguez
Juan Francisco Oteo Domínguez
MMMaría Mateos-Seirul
María Mateos-Seirul
ERElsa Carolina Rios Rosado
Elsa Carolina Rios Rosado
AFAlberto Forteza-Gil
Alberto Forteza-Gil
Background: Infective endocarditis (IE) is a feared complication after surgical aortic valve replacement (SAVR)/transcatheter aortic valve implantation (TAVI). It is not certain which procedure carries a higher risk. Our aim was to assess the risk of IE after SAVR/TAVI. Methods: We conducted an observational study of a prospective cohort, including patients with TAVI/SAVR, from March 2015 to December 2020. IE was defined according to the modified Duke’s criteria. IE occurring during the first 12 months of the procedure was considered early IE, and an episode occurring after 12 months was considered late IE. The propensity score was designed to include variables previously associated with TAVI/SAVR and IE. An inverse probability of treatment weight was generated. Results: In total, 355 SAVR and 278 TAVI were included. Median follow-up, 38 vs. 41 months, p = 0.550. IE occurred in 5 SAVR (1.41%, 95% CI 0.2–2.6) vs. 13 TAVI (4.65%, 95% CI 2.2–7.2), p = 0.016. TAVI patients had more frequent early IE (3.2% vs. 0.3%, p = 0.006). In the PS analyses, IE risk did not differ: OR 0.65, 95% CI 0.32–1.32. Factors associated with TAVI IE included younger age (74y vs. 83y, p = 0.030), complicated diabetes mellitus (38.5% vs. 6.8%, p = 0.002), COPD (46.2% vs. 16.3%, p = 0.015), advanced heart failure (100% vs. 52.9%, p < 0.001), and peripheral arteriopathy (61.5% vs. 26.7%, p = 0.011). Conclusions: Early IE was higher with TAVI, but in the PS analyses, the risk attributable to each procedure was similar. Studies are needed to identify and optimize the risk factors of IE prior to TAVI.

25 September 2018 in Medical Sciences
Verified
Journal Article
Open access
PDF file
RRRosa Malo de Molina Ruiz
Rosa Malo de Molina Ruiz
SISilvia Aguado Ibáñez
Silvia Aguado Ibáñez
CSCarlos Arellano Serrano
Carlos Arellano Serrano
MVManuel Valle
Manuel Valle
MGMARIA PIEDAD USSETTI GIL
MARIA PIEDAD USSETTI GIL
Patients with chronic obstructive pulmonary disease (COPD) have a higher risk of acute cardiovascular events, and around 30% die from cardiovascular diseases. Recent data suggest an increased risk of myocardial infarction in the following days of a severe exacerbation of COPD. Disruption in the balance during the exacerbation with tachycardia, increased inflammation and systemic oxidative stress as well as some other factors may confer an increased risk of subsequent cardiovascular events. A number of investigations may be useful to an early diagnosis, including electrocardiography, imaging techniques and blood test for biomarkers. Some drugs that have changed prognosis in the cardiovascular setting such as cardioselective beta-blockers may be underused in patients with COPD despite its demonstrated benefits. This review focuses on several aspects of exacerbation of COPD and cardiovascular events including epidemiology, possible mechanism, diagnosis and treatment.

1 October 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
PMP Vela Martin
P Vela Martin
CSCarlos Arellano Serrano
Carlos Arellano Serrano
VUV Castro Urda
V Castro Urda
DRD Garcia Rodriguez
D Garcia Rodriguez
FTF Hernandez Terciado
F Hernandez Terciado
JDJuan Francisco Oteo Domínguez
Juan Francisco Oteo Domínguez
Introduction: Permanent pacing is often needed in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) due to new onset conduction disorders. Nevertheless, continuous right ventricular pacing may deteriorate left ventricular ejection fraction (LVEF) and lead to poor outcomes. Thus, in last years, more physiological forms of pacing, such as left bundle branch pacing (LBBP) have been developed to prevent pacing induced cardiomyopathy. Purpose: The aim of our study is to describe the initial experience in our center, evaluate the safety and feasibility of LBBP after TAVI and describe electrophysiological outcomes in the first months of follow-up. Methods: We designed a prospective registry that collected all patients from the TAVI program of our center who developed conduction abnormalities in the immediate postoperative and received LBBP. We analyzed baseline characteristics, complications and procedure time, electrophysiological parameters after the procedure and final QRS interval. During follow-up LVEF, electrophysiological parameters and adverse clinical events (readmissions for heart failure, cardiovascular mortality and all-cause of mortality) were also evaluated at 3rd, 6th and 12th month. Results: Between January 2020 and January 2022, twenty patients who developed conduction abnormalities after TAVI underwent LBBP. Seven patients (35%) had a complete atrioventricular block, two patients (10%) alternating bundle branch block and 11 (55%) had a new left bundle branch block. HV electrophysiology study was performed in 8 patients, with a median value of 68ms (66–72). Of the 20 patients, 3 out of 4 patients were male and had history of hypertension. 40% had previous ischemic heart disease and one patient had transthyretin cardiac amyloidosis. Median age was 79 years-old (76–83.5). Balloon-expandable prosthesis was implanted in 11 patients while 9 received a self-expandable prosthesis. Median basal LVEF was 59% (41.5–60) and median NTproBNP was 1722pg/ml (535–5848). LBBP was successful in all of the 20 patients. The median time of the procedure was 60 minutes (45–80) without suffering any complications. The median QRS interval before the procedure was 155ms (140–158) and 116ms (105–125) post-implant. To date, two patients have died of non-cardiac cause 3 and 8 months after LBBP. There have been no readmissions for heart failure. LVEF (pre and post-LBBP) and electrophysiological parameters post-implant and three-month follow-up are shown in Table 1. Conclusions: In our experience, LBBP after TAVI is a safe and feasible procedure. Despite the small sample size and short follow-up period, our first results indicate stability of LVEF and pacemaker parameters. Funding Acknowledgement: Type of funding sources: None.

1 July 2016 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
MRMaria Alejandra Restrepo-Cordoba
Maria Alejandra Restrepo-Cordoba
CSCarlos Arellano Serrano
Carlos Arellano Serrano
SMSusana Mingo-Santos
Susana Mingo-Santos

Verified
Conference Paper
Open access
WLWanming Liu
Wanming Liu
LDLawrence Doolittle
Lawrence Doolittle
DDDarrell Doran
Darrell Doran
DFDaniele Filippetto
Daniele Filippetto
GHGwanghui Ha
Gwanghui Ha
EWEric Wisniewski
Eric Wisniewski
The Argonne Wakefiled Accelerator (AWA) Test Facility designed and operated a homemade LLRF system for the last 20 years. It is based on NI-PXI products that has now become obsolete. The AWA’s LLRF cannot keep up with the increasing stability demands of AWA’s upgraded facility. An overhaul of the system is strongly desired. With the support from DOE-HEP, the AWA is collaborating with Lawrence Berkeley National Laboratory (LBNL)to upgrade its LLRF system with modern instrumentation to meet the growing stability demands. An overview of AWA’s current LLRF system performance is presented together with the upgrade plan and expectations.

19 May 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
KHKimberley Iris Hemelrijk
Kimberley Iris Hemelrijk
MNMatias R Mon Noboa
Matias R Mon Noboa
GTGabriela Tirado‐Conte
Gabriela Tirado‐Conte
TWToon Winkelman
Toon Winkelman
LALluís Asmarats
Lluís Asmarats
LNLuis Nombela
Luis Nombela
Background: Transcatheter aortic valve replacement (TAVR) has shown noninferiority to surgical aortic valve replacement (SAVR). However, patients with bicuspid aortic stenosis are often excluded from these studies. More insights between these procedures in this population is crucial for treatment selection. Methods: In this multicenter observational study, patients with bicuspid aortic stenosis undergoing TAVR or SAVR were analyzed using propensity score matching. The primary outcome was a composite of all‐cause mortality, stroke, rehospitalization, or valve dysfunction at 1 year. Results: A total of 997 patients with bicuspid aortic stenosis underwent TAVR or SAVR. In the matched cohort of 256 pairs, the median age was 75.0 years (interquartile range, 71.0–78.0), 234 (44.9%) were women, and the median EuroScore II was 1.83% (interquartile range, 1.34–2.86). One‐year cumulative incidence of the primary outcome was 15.0% in TAVR compared with 12.0% in SAVR (hazard ratio [HR], 1.35 [95% CI, 0.83–2.19], P =0.23). Mortality (4.3% versus 5.0%, P =0.72) and rehospitalization (4.8% versus 6.4%, P =0.45) were similar between groups. Although rates of valve dysfunction (2.9% versus 0.5%, P =0.06) and stroke (5.3% versus 2.3%, P =0.10) were numerically lower in the surgical group at 1 year, both the risk of stroke (subdistribution HR, 3.01, P =0.02) and valve dysfunction (subdistribution HR, 4.16, P =0.03) were significantly higher in the TAVR group at 2 years. Conclusions: TAVR in patients with bicuspid aortic stenosis showed a similar 1‐year primary outcome rate compared with SAVR, though TAVR exhibited higher rates of valve dysfunction and stroke. These findings underscore the need for randomized trials to define the optimal treatment strategy for this population.